Kratom, scientifically known as Mitragyna speciosa, is native to Southeast Asia and has been used for medicinal purposes, cultural rituals, and productivity enhancement for thousands of years. Kratom contains over 40 different alkaloids, with mitragynine and its oxidized metabolite 7-hydroxymitragynine (7-OH) being the most significant for their biological and psychoactive effects.
Alkaloid Composition and Effects
Mitragynine accounts for up to two-thirds of Kratom’s total alkaloid content and represents 1% to 2% of the dry leaf mass. In contrast, 7-OH is present in much smaller amounts, typically less than 0.05% of the dry leaf mass. Despite its lower concentration, 7-OH plays a crucial role in Kratom’s analgesic properties and exhibits significantly higher affinity for the mu-opioid (μ) receptor compared to mitragynine and even morphine.
Studies reveal that while mitragynine itself does not directly activate opioid receptors significantly, its metabolism to 7-OH enhances its pain-relieving potency. This metabolite also contributes to respiratory depressive effects and is substantially more potent than mitragynine. However, natural Kratom leaves in typical doses do not contain enough 7-OH to produce direct opioid-like effects in humans.
Concerns About Adulteration and Synthetic Products
In the United States, where an estimated 3.3 million people have used Kratom at least once, concerns about adulteration have emerged. Studies from 2016 revealed that some commercial Kratom products had artificially elevated 7-OH levels, with concentrations up to 500% higher than those found in natural Kratom leaves.
Recently, experts have warned about new semi-synthetic 7-OH Kratom products. These include sublingual tablets and nasal sprays containing up to 98% 7-OH alongside other alkaloids. Researchers caution that these products pose health risks due to their uncertain chemical compositions and the known pharmacology of 7-OH. Differentiating between natural Kratom and these semi-synthetic substances is critical, as the latter complicates regulatory oversight and increases the risk of misuse.
Regulatory and Health Implications
Leading researchers have emphasized that 7-OH products should not be considered Kratom, either scientifically or commercially. These substances raise significant regulatory and health concerns, underscoring the need for enhanced oversight and clinical research. Legislators must distinguish between Kratom and 7-OH products to ensure accurate regulation and prevent the mislabeling of adulterated products as natural Kratom.
Moving Forward
Understanding the pharmacological profile and therapeutic potential of 7-OH is essential to addressing health concerns. A balanced regulatory approach can help protect consumers while preserving Kratom’s traditional and medicinal applications. Further research and oversight are vital to ensuring the safe use of this complex plant and its derivatives.
References/Referenzen:
- Hassan Z, Muzaimi M, Navaratnam V, Yusoff NHM, Suhaimi FW, Vadivelu R, et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013 Feb;37(2):138–51.
- Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: Results from an online survey. Drug Alcohol Depend. 2019;202:24–32.
- Bath R, Bucholz T, Buros AF, Singh D, Smith KE, Veltri CA, et al. Self-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey. J Addict Med [Internet]. 2020;14(3). Available from: https://journals.lww.com/journaladdictionmedicine/fulltext/2020/06000/self_reported_health_diagnoses_and_demographic.11.aspx
- Saingam D, Assanangkornchai S, Geater AF, Balthip Q. Pattern and consequences of krathom (Mitragyna speciosa Korth.) use among male villagers in southern Thailand: a qualitative study. Int J Drug Policy. 2013 Jul;24(4):351–8.
- Kruegel AC, Gassaway MM, Kapoor A, Váradi A, Majumdar S, Filizola M, et al. Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. J Am Chem Soc. 2016 Jun 1;138(21):6754–64.
- Basiliere S, Brower J, Winecker R, Friederich L, Kerrigan S. Identification of five mitragyna alkaloids in blood and tissues using liquid chromatography-quadrupole/time-of-flight mass spectrometry. Forensic Toxicol. 2020 Jul 1;38(2):420–35.
- Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, et al. Following “the Roots” of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. BioMed Res Int. 2015;2015:968786.
- Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2018 May 15;134(Pt A):108–20.
- Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo). 2004 Aug;52(8):916–28.
- Kikura-Hanajiri R, Kawamura M, Maruyama T, Kitajima M, Takayama H, Goda Y. Simultaneous analysis of mitragynine, 7-hydroxymitragynine, and other alkaloids in the psychotropic plant “kratom” (Mitragyna speciosa) by LC-ESI-MS. Forensic Toxicol. 2009 Jul 1;27(2):67–74.
- Ponglux D, Wongseripipatana S, Takayama H, Kikuchi M, Kurihara M, Kitajima M, et al. A New Indole Alkaloid, 7 alpha-Hydroxy-7H-mitragynine, from Mitragyna speciosa in Thailand. Planta Med. 1994 Dec;60(6):580–1.
- Todd DA, Kellogg JJ, Wallace ED, Khin M, Flores-Bocanegra L, Tanna RS, et al. Chemical composition and biological effects of kratom (Mitragyna speciosa): In vitro studies with implications for efficacy and drug interactions. Sci Rep. 2020 Nov 5;10(1):19158.
- Chakraborty S, Uprety R, Slocum ST, Irie T, Le Rouzic V, Li X, et al. Oxidative Metabolism as a Modulator of Kratom’s Biological Actions. J Med Chem. 2021;64(22):16553–72.
- Matsumoto K, Horie S, Ishikawa H, Takayama H, Aimi N, Ponglux D, et al. Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2004 Mar;74(17):2143–55.
- Rosenbaum CD, Carreiro SP, Babu KM. Here Today, Gone Tomorrow…and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines. J Med Toxicol. 2012 Mar 1;8(1):15–32.
- Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, et al. 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Cent Sci. 2019 Jun 26;5(6):992–1001.
- Hill R, Kruegel AC, Javitch JA, Lane JR, Canals M. The respiratory depressant effects of mitragynine are limited by its conversion to 7‐OH mitragynine. Br J Pharmacol. 2022 Jul;179(14):3875–85.
- Schimmel J, Amioka E, Rockhill K, Haynes CM, Black JC, Dart RC, et al. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study. Addict Abingdon Engl. 2021 Jan;116(1):176–81.
- Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. J Med Toxicol. 2016 Dec;12(4):341–9.
- Smith KE, Boyer EW, Grundmann O, McCurdy CR, Sharma A. The rise of novel, semi-synthetic 7-hydroxymitragnine products. Addiction [Internet]. 2024 Dec 3 [cited 2025 Jan 7];n/a(n/a). Available from: https://doi.org/10.1111/add.16728